Quarterly ResultMay 15, 2026, 01:41 PM
Retractable Technologies Q1 Sales Down 13.5% to $7.18M; EPS ($0.14)
AI Summary
Retractable Technologies reported a 13.5% decrease in net sales to $7.18 million for the first quarter of 2026, with gross loss widening significantly to $838,408 and operating loss increasing to $6.17 million. Despite these operational challenges, the net loss applicable to common shareholders improved to ($4.28 million) or ($0.14) per share, primarily due to an unrealized gain on debt and equity securities. The company also recorded $863,037 in inventory write-downs and continues to face material impacts from 110% tariffs on Chinese syringe and needle imports.
Key Highlights
- Net sales decreased 13.5% to $7.18 million for Q1 2026 compared to Q1 2025.
- Gross loss widened significantly to $838,408 from $1,911 in the prior year period.
- Loss from operations increased to $6.17 million from $4.68 million.
- Net loss applicable to common shareholders improved to ($4.28 million) from ($10.56 million).
- Basic loss per share improved to ($0.14) from ($0.35).
- The company recorded $863,037 in inventory write-downs for the quarter.
- U.S. sales declined to $5.95 million from $7.43 million in the comparable period.
- Tariffs on most syringe and needle products imported from China remain at 110%.
Price Impact
More from RVP